Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × cabozantinib × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Recruiting 6 Completed 5 Terminated 3 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

Cyclophosphamide 22 pembrolizumab 19 Cisplatin 15 Nivolumab 14 Fluorouracil 14 Capecitabine 13 Leucovorin 12 Carboplatin 12 Bevacizumab 12 Oxaliplatin 11 Radiotherapy 10 Lenalidomide 10 Dexamethasone 10 fludarabine 9 avelumab 9 Taxes 9 Rituximab 9 Gemcitabine 9 Radiosurgery 8 Azacitidine 8 venetoclax 7 fludarabine phosphate 7 Irinotecan 7 Ipilimumab 7 Docetaxel 7 ALT-803 7 Omacor 6 Melphalan 6 Interleukin-2 6 Etoposide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡